Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for members of an interprofessional team managing the care of patients with multiple myeloma and its related conditions and sequelae.

**Objectives:**
- Identify the indications for ixazomib therapy. 
- Identify the most common adverse events associated with ixazomib therapy.
- Explain the importance of monitoring for patients on ixazomib therapy, including what factors should be monitored specifically. 
- Summarize the risks associated with initiating ixazomib and summarize key patient counseling points.